Foundational guide
Bronchogen Peptide: Verifying a Record That Is Mostly Not There
Two searches, two artefacts. About three quarters of the apparent literature is a different disease, and the single registry record is a diagnostic device from another company.
Bronchogen is a four residue peptide, Ala-Asp-Glu-Leu. Verifying what is known about it is unusually instructive, because both of the searches a reader would run return results that are mostly about something else, and in each case the reason is mechanical rather than medical.
The method below is the same one applied to every compound on this site: read what produced each record before counting it.
Artefact one: the literature count
A PubMed search on the name returns roughly twelve records. Counting them without reading them produces a figure about four times larger than the evidence base.
Most of the returned titles concern bronchogenic cysts and bronchogenic carcinoma, which share a word stem and nothing else. Filtered to the compound, the record is this:
| Year | What was examined | Organism | Tier |
|---|---|---|---|
| 2011 | Effect on DNA thermostability (PMID 21240358) | In vitro | Three |
| 2015 | Bronchial epithelium, induced obstructive lung pathology (PMID 26468022) | Rat | Two |
| 2017 | Anti-inflammatory and regenerative effect, same model (PMID 30199201) | Rat | Two |
The 2011 paper is also the source for the sequence, which is worth noting because a sequence without a citation is one of the commonest unsourced claims in this category.
Artefact two: the registry record
ClinicalTrials.gov returns one record for the name. Read three fields before the number and it resolves immediately.
NCT00746759 is titled “Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS IDE”. Its study type is observational. Its lead sponsor is Allegro Diagnostics. Its listed intervention is a diagnostic device, annotated in the record itself as not used as an intervention, and its stated purpose is identifying gene expression patterns in smokers that indicate lung cancer earlier than imaging would.
Allegro used the name BronchoGen for a diagnostic test. The registry search matched a string. This is the same failure mode as an NCT number cited for the wrong compound, with the difference that here nobody constructed it: the collision is accidental.
A fuller reference on the compound and how it is sold is available in this guide to the bronchogen peptide.
The generalisable check
Two habits catch both artefacts and cost about a minute. In a literature search, read titles before counts, because any compound whose name carries a common medical root will return an inflated figure. In a registry search, read study type and lead sponsor before the identifier, because a registration proves a submission was accepted and nothing further.
Applied here, those two habits reduce a compound that appears to have a literature and a trial to one that has three animal and in vitro papers and neither.
Frequently asked questions
- How many registered human trials exist for this compound?
- None. A registry search on the name returns one record, NCT00746759, which is an observational lung cancer diagnostic study sponsored by Allegro Diagnostics. Its study type and lead sponsor both disqualify it as a trial of the peptide.
- Why does the PubMed count overstate the literature?
- Because the term matches the stem in bronchogenic cyst and bronchogenic carcinoma, unrelated conditions. Of roughly twelve records returned, about three concern the peptide.
- What evidence tier does the compound reach?
- Tier three and tier two. One in vitro thermostability assay, and two rat studies in an induced obstructive lung model. No tier one human data exists.
- Is the sequence documented?
- Yes. Ala-Asp-Glu-Leu, stated in the 2011 paper on DNA thermostability, PMID 21240358.
- Has the animal work been replicated outside its originating group?
- No independent replication was identified. The papers sit within the Russian bioregulator tradition that also produced epithalon, and the same caution applies to both.
Limitations of the evidence
This page evaluates the provenance of a record and prints no administration guidance, no quantity and no schedule. Bronchogen holds no marketing authorisation in any market and is sold as a research chemical. Its published literature is three items: one in vitro assay and two rat studies in an induced obstructive lung model, all from a single research tradition, with no independent replication identified outside it. No human study of the compound has been registered or published, so no efficacy or safety claim about people can be graded at any tier here. Nothing in this page describes or recommends human use.